Moteur de recherche d’entreprises européennes
Financement de l’UE (8 291 218 €) : Mise à l’échelle de nanomédicaments biodégradables pour l’immunothérapie multimodale de précision du cancer Hor 06/04/2016 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Mise à l’échelle de nanomédicaments biodégradables pour l’immunothérapie multimodale de précision du cancer
PRECIOUS aims at scaling-up biodegradable nanomedicines for multimodal precision cancer immunotherapy. With 3.5 million cancer patients in Europe every year, new cancer medicines are eagerly awaited, notably for prostate and ovarian cancer. Systemically applied new immunotherapies are promising, but their toxicity is a hurdle. Vaccination against cancer is safe but rather the efficacy can be disappointing, i.e. the microenvironment shuts down anti-tumour immunity. PRECIOUS will tackle 2 bottlenecks: 1. Production of non toxic multimodal nanomedicines, which induce vigorous immune responses, and at the same time reverse immunosuppression 2. Large scale GMP production of nanomedicines, and initiate a multimodal immunotherapy Phase I trial. We want to solve these bottlenecks by: Objective 1: Two types of GMP biodegradable nanoparticles: 1) a nanovaccine, containing tumour antigens and immune activators, and 2) a nanoparticle composed of compounds, which reverses the suppression and reactivates immunity in the tumour. Objective 2: Clinical Phase I trial to show efficacy. Nanomedicines will be used by 1) injection of vaccines to evoke immune responses and 2) injection of nanoparticles in the tumour microenvironment, which slowly release compounds that reverse suppression. To achieve this, a platform is formed with 6 leading industrial partners to produce large scale GMP nanomedicines and an excellent immunomodulator track record, together with 5 renowned academic partners to perform clinical studies. Relevance to call: Large scale GMP production, industrial leadership, nanotechnology and advanced manufacturing KET technologies, translation to the clinic, marketing development.
| Evonik Operations GmbH | 835 738 € |
| Fondazione Irccs Istituto Nazionale DEI Tumori | 448 417 € |
| IOX Therapeutics Ltd. | 241 483 € |
| Iteos Therapeutics | 949 030 € |
| Molecure SA | 615 783 € |
| PNO Life Sciences & Health B.V. | 159 062 € |
| Specialized Medical Services-Oncology B.V. | 720 266 € |
| Stichting Radboud Universitair Medisch Centrum | 637 983 € |
| Stichting Radboud Universiteit | 1 771 695 € |
| The Chancellor, Masters and Scholars of the University of Oxford | 712 254 € |
| Universitat Konstanz | 735 651 € |
| Ustav Makromolekularni Chemie AV Crvvi | 463 855 € |
https://cordis.europa.eu/project/id/686089
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.